Quest Diagnostics (DGX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Here is how Quest Diagnostics (DGX) and DaVita HealthCare (DVA) have performed compared to their sector so far this year.
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock?
Quest Diagnostics gains from DIS growth, advanced diagnostics uptake and AI-driven efficiencies, though debt levels and healthcare reimbursement risks remain concerns.
Guidance upgrades are generally among the most bullish announcements a company can make, signaling that the outlook is even better than previously expected.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Quest Diagnostics Incorporated (NYSE:DGX) on Tuesday reported upbeat earnings for the first quarter on Tuesday.
On April 21, 2026, Quest Diagnostics Inc (DGX) shares rose 4.5% to a current price of $205.04. This move is part of a broader uptrend, with the stock experienci
Quest Diagnostics Incorporated (DGX) Q1 2026 Earnings Call Transcript
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.